Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis
IntroductionSeveral small sample-sized clinical trials have demonstrated a beneficial effect of statin on depressive mood among major depressive disorder (MDD) patients. However, observational studies have showed the increased risk of anxiety/depression with statin treatment. Therefore, we aimed to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1203444/full |
| _version_ | 1797614204350365696 |
|---|---|
| author | Xue Xiao Hu Deng Peng Li Jifei Sun Jing Tian |
| author_facet | Xue Xiao Hu Deng Peng Li Jifei Sun Jing Tian |
| author_sort | Xue Xiao |
| collection | DOAJ |
| description | IntroductionSeveral small sample-sized clinical trials have demonstrated a beneficial effect of statin on depressive mood among major depressive disorder (MDD) patients. However, observational studies have showed the increased risk of anxiety/depression with statin treatment. Therefore, we aimed to evaluate the effects of statin on depressive mood and inflammation status among MDD patients.MethodsWe performed an updated meta-analysis RCTs identified in systematic searches of PubMed, Cochrane library, Embase, ClinicalTrials.gov, CNKI, Wan fang, VIP, and SinoMed database (up to August 2023). The primary endpoint was the Hamilton depression rating scale (HDRS). The secondary endpoints were rate of response to treatment, remission rate, levels of C-reactive protein (CRP), cognition and blood lipid. We evaluated the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.ResultsThe search identified seven RCTs involving 448 patients with a median follow-up of 10.4 weeks (range, 6–12 weeks). Compared with selective serotonin reuptake inhibitors (SSRIs) alone, treatment with statin plus SSRIs was associated with a significantly decreased HDRS [mean difference (MD) = −2.79; 95% confidence interval (CI): −3.83 to −1.76] and C-reactive protein (MD = −0.42 mg/L; 95% CI: −0.53 to −0.12 mg/L), and decreased levels of lipid profiles (P < 0.05). Moreover, statin plus SSRIs was associated with a comparable rate of treatment response [relative risk (RR) = 1.26; 95% CI: 0.98 to 1.62], remission rate (RR = 1.33; 95% CI: 0.89 to 1.99). Meta-regression indicated that the follow-up period was a source of heterogeneity regarding the HDRS (r = 0.302, P = 0.041). The quality of evidence was rated as moderate for HDRS and response rate according to the GRADE.ConclusionStatin could safely and effectively improve the symptoms of depression and inflammation status among MDD patients.Systematic review registrationhttps://inplasy.com/inplasy-2022-3-0016/, identifier INPLASY2022230016. |
| first_indexed | 2024-03-11T07:05:30Z |
| format | Article |
| id | doaj.art-5b12c5d73c7d4751a17f1b2ca362ab92 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-03-11T07:05:30Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-5b12c5d73c7d4751a17f1b2ca362ab922023-11-17T08:56:06ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-11-011410.3389/fpsyt.2023.12034441203444Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysisXue Xiao0Hu Deng1Peng Li2Jifei Sun3Jing Tian4Department of Psychiatric, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing, ChinaDepartment of Innovation and Transformation, Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, ChinaThe Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, ChinaDepartment of Radiology, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing, ChinaDepartment of Psychiatric, Beijing First Hospital of Integrated Chinese and Western Medicine, Beijing, ChinaIntroductionSeveral small sample-sized clinical trials have demonstrated a beneficial effect of statin on depressive mood among major depressive disorder (MDD) patients. However, observational studies have showed the increased risk of anxiety/depression with statin treatment. Therefore, we aimed to evaluate the effects of statin on depressive mood and inflammation status among MDD patients.MethodsWe performed an updated meta-analysis RCTs identified in systematic searches of PubMed, Cochrane library, Embase, ClinicalTrials.gov, CNKI, Wan fang, VIP, and SinoMed database (up to August 2023). The primary endpoint was the Hamilton depression rating scale (HDRS). The secondary endpoints were rate of response to treatment, remission rate, levels of C-reactive protein (CRP), cognition and blood lipid. We evaluated the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.ResultsThe search identified seven RCTs involving 448 patients with a median follow-up of 10.4 weeks (range, 6–12 weeks). Compared with selective serotonin reuptake inhibitors (SSRIs) alone, treatment with statin plus SSRIs was associated with a significantly decreased HDRS [mean difference (MD) = −2.79; 95% confidence interval (CI): −3.83 to −1.76] and C-reactive protein (MD = −0.42 mg/L; 95% CI: −0.53 to −0.12 mg/L), and decreased levels of lipid profiles (P < 0.05). Moreover, statin plus SSRIs was associated with a comparable rate of treatment response [relative risk (RR) = 1.26; 95% CI: 0.98 to 1.62], remission rate (RR = 1.33; 95% CI: 0.89 to 1.99). Meta-regression indicated that the follow-up period was a source of heterogeneity regarding the HDRS (r = 0.302, P = 0.041). The quality of evidence was rated as moderate for HDRS and response rate according to the GRADE.ConclusionStatin could safely and effectively improve the symptoms of depression and inflammation status among MDD patients.Systematic review registrationhttps://inplasy.com/inplasy-2022-3-0016/, identifier INPLASY2022230016.https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1203444/fulldepressionstatinmoodinflammationmeta-analysis |
| spellingShingle | Xue Xiao Hu Deng Peng Li Jifei Sun Jing Tian Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis Frontiers in Psychiatry depression statin mood inflammation meta-analysis |
| title | Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis |
| title_full | Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis |
| title_fullStr | Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis |
| title_full_unstemmed | Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis |
| title_short | Statin for mood and inflammation among adult patients with major depressive disorder: an updated meta-analysis |
| title_sort | statin for mood and inflammation among adult patients with major depressive disorder an updated meta analysis |
| topic | depression statin mood inflammation meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1203444/full |
| work_keys_str_mv | AT xuexiao statinformoodandinflammationamongadultpatientswithmajordepressivedisorderanupdatedmetaanalysis AT hudeng statinformoodandinflammationamongadultpatientswithmajordepressivedisorderanupdatedmetaanalysis AT pengli statinformoodandinflammationamongadultpatientswithmajordepressivedisorderanupdatedmetaanalysis AT jifeisun statinformoodandinflammationamongadultpatientswithmajordepressivedisorderanupdatedmetaanalysis AT jingtian statinformoodandinflammationamongadultpatientswithmajordepressivedisorderanupdatedmetaanalysis |